|
|
|
|
Дата |
|---|
| 17:53 |
| 24.07.2026 |
| 23.07.2026 |
| 22.07.2026 |
| 21.07.2026 |
| 20.07.2026 |
| 17.07.2026 |
| 16.07.2026 |
| 15.07.2026 |
| 14.07.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
13.58
|
13.67
|
12.98
|
11.27
|
14.50
|
13.59
|
|
|
40 588 651.77
|
20 503.00
|
|
32.12
|
40.00
|
35.46
|
34.38
|
36.97
|
36.56
|
|
|
19 771 420.66
|
6 557.00
|
|
32.13
|
40.00
|
34.86
|
34.495
|
36.035
|
35.23
|
|
|
13 252 959.86
|
6 366.00
|
|
32.12
|
40.00
|
37.70
|
35.28
|
37.70
|
35.31
|
|
|
9 560 645.75
|
6 717.00
|
|
19.02
|
40.00
|
37.30
|
36.03
|
38.26
|
37.44
|
|
|
20 795 714.93
|
8 688.00
|
|
33.70
|
40.00
|
38.11
|
35.97
|
38.925
|
35.99
|
|
|
22 291 443.28
|
8 229.00
|
|
19.02
|
40.00
|
36.37
|
35.52
|
38.625
|
37.87
|
|
|
29 227 030.64
|
9 208.00
|
|
19.02
|
40.00
|
36.77
|
35.935
|
38.005
|
37.22
|
|
|
36 248 746.11
|
10 691.00
|
|
19.02
|
40.00
|
37.54
|
35.52
|
37.78
|
37.33
|
|
|
25 802 585.36
|
11 436.00
|
|
23.00
|
40.00
|
36.84
|
35.28
|
38.16
|
37.91
|
|
|
10 186 963.56
|
5 267.00
|
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded by leading experts in psychiatry and neuroscience, dedicated to addressing significant unmet medical needs in central nervous system (CNS) disorders. The firm’s proprietary discovery platform-leveraging optogenetics, spatial transcriptomics (STARmap) and circuit-based neuroscience-aims to identify and modulate the specific neural circuits underlying diseases. Their lead candidate, ML-007C-MA (an M/M muscarinic agonist co-formulated with a peripherally acting anticholinergic), is currently in Phase 2 development for indications including schizophrenia and Alzheimer’s disease psychosis.
The company is headquartered in Redwood City, California, and recently completed a large Series D financing of US $372.5 million to advance its pipeline.
Показать все Скрыть